tegafur has been researched along with Obesity in 2 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
Excerpt | Relevance | Reference |
---|---|---|
"Medroxyprogesterone acetate (MPA) plus Tegafur (TGF) therapy was performed to evaluate the efficacy in a treatment for Tamoxifen- and Adriamycin-resistant advanced breast cancers." | 7.67 | [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers]. ( Aizawa, M; Houjou, T; Kadota, K; Kurooka, K; Matunami, N; Mori, N; Morikawa, E; Nakano, K; Wada, T; Yamato, M, 1989) |
"Medroxyprogesterone acetate (MPA) plus Tegafur (TGF) therapy was performed to evaluate the efficacy in a treatment for Tamoxifen- and Adriamycin-resistant advanced breast cancers." | 3.67 | [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers]. ( Aizawa, M; Houjou, T; Kadota, K; Kurooka, K; Matunami, N; Mori, N; Morikawa, E; Nakano, K; Wada, T; Yamato, M, 1989) |
" However, there is a paucity of data from sufficiently powered pharmacokinetic and pharmacodynamic studies to support dosage recommendations in such patients." | 2.50 | Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'. ( Fujita, K; Sasaki, Y, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujita, K | 1 |
Sasaki, Y | 1 |
Wada, T | 1 |
Matunami, N | 1 |
Houjou, T | 1 |
Morikawa, E | 1 |
Mori, N | 1 |
Nakano, K | 1 |
Aizawa, M | 1 |
Kurooka, K | 1 |
Kadota, K | 1 |
Yamato, M | 1 |
1 review available for tegafur and Obesity
Article | Year |
---|---|
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationsh | 2014 |
1 other study available for tegafur and Obesity
Article | Year |
---|---|
[Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Evaluation; Drug Resistance; Drug Therapy, Combinat | 1989 |